<DOC>
	<DOCNO>NCT00771849</DOCNO>
	<brief_summary>The study investigate safety profile antibody responses experimental tetravalent meningococcal diphtheria conjugate vaccine ( Menactra® ) child receive monovalent meningococcal C conjugate vaccine least one year previously . Primary objective : To describe compare Serum Bactericidal Assay ( SBA ) antibody response serogroup C participant receive Menactra® serogroup C antibody response control group participant receive licensed Haemophilus Influenzae Type b ( Hib ) conjugate vaccine 28 day follow vaccination .</brief_summary>
	<brief_title>Study Antibody Responses After Dose Tetravalent Meningococcal Diphtheria Conjugate Vaccine Children</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Inclusion Criteria : Participant healthy , determined medical history physical examination . Participant 2 year &lt; 5 year age time vaccination . At least one year primary vaccination monovalent meningococcal C conjugate vaccine elapse . Parent/Guardian sign Ethics Committeeapproved inform consent form . A culturally appropriate translation use nonEnglish speaking participant require . Exclusion Criteria : Serious chronic disease ( i.e . cardiac , renal , neurologic , metabolic , rheumatologic , etc . ) Known suspect impairment immunologic function Acute medical illness without fever within last 72 hour axillary temperature ≥ 37.5ºC time inclusion History document invasive meningococcal disease Administration immune globulin , blood product within last three month , injected oral corticosteroid immunomodulatory therapy within six week study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day may include trial long receive one course within last two week prior enrolment Antibiotic therapy within 72 hour prior vaccination 72 hour prior draw blood sample Received vaccine 28day period prior enrolment , schedule receive vaccine enrolment trial Received meningococcal C conjugate vaccine within one year prior enrolment Suspected known hypersensitivity vaccine component Unavailable entire study period unable attend schedule visit comply study procedure Enrolled another clinical trial Any condition , , opinion investigator , would pose health risk participant interfere evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcemia</keyword>
	<keyword>Neisseria meningitidis</keyword>
</DOC>